Vera's Trutakna generates $10.3m in third quarter as company seeks full US approval

Vera Therapeutics recorded net sales of $10.3m for Trutakna (atacicept-vymj) in the third quarter of 2026, according to results released on 5 November. It is the first revenue the company has earned from a marketed medicine.

The drug is approved in the US to reduce proteinuria in adults with primary IgA nephropathy (IgAN). The FDA granted that clearance on 7 July under the accelerated pathway, so the quarterly figure reflects the months since launch. The company gave no further sales detail in the material available to us.

Two days before reporting, on 3 November, Vera sent the agency a supplemental biologics licence application seeking full approval. The submission draws on two-year results from the ORIGIN 3 study. Vera expects an FDA decision in mid-2027.

Vera also plans to apply to the European Medicines Agency for marketing authorisation in the first quarter of 2027. No European timetable beyond that filing has been disclosed.

By way of context, accelerated approval lets a drug reach patients on the strength of a surrogate marker, such as lower proteinuria. Continued marketing normally depends on later evidence of clinical benefit, which is what a conversion to full approval would formalise.